Table 1.

The characteristics of the patients undergoing Re-LDLT

Era of Re-LDLT	Patient no.	Gender	Age (years)	Primary disease	Interval after primary LDLT (days)	BW (kg)	Cause of graft loss	MELD/PELD score	Operative time (min)	Bleeding (mL/kg)	Type of graft	Outcome
1998–2009	1	M	0.8	BA	9	7.3	Vascular complication	25	415	66	Left lateral	Alive
	2	F	5.7	BA	782	16.3	Sclerosing cholangitis	2	587	21	Left lateral	Alive
	3	M	15.1	BA	52	38.6	Vascular complication	39	1163	104	Left	Expired (POD11)
	4	F	14.2	BA	4834	50.0	Steatohepatitis	18	1981	720	Left	Expired (POD2)
	5	F	15.8	Wilson	271	54.5	Refractory acute rejection	22	1000	118	Right	Alive
	6	F	12.3	PFIC-1	3154	21.0	Chronic rejection	26	970	798	Left	Expired (POD1540)
2010–2015	7	M	3.5	ALF	1090	13.0	Chronic rejection	2	946	372	Left lateral	Alive
	8	F	7.7	PSC	854	17.0	PSC recurrence	60	607	377	Left lateral	Alive
	9	F	4.2	BA	861	13.0	Refractory acute rejection	8	990	177	Left lateral	Alive
	10	M	13.3	PFIC-1	3521	30.0	Steatohepatitis	11	681	153	Left	Alive
	11	F	0.8	BA	109	6.3	Chronic rejection	24	601	67	Left lateral	Alive
	12	M	1.3	BA	252	8.6	Biliary complication	9	685	50	Left lateral	Alive
	13	F	14.8	BA	5072	43.0	Chronic rejection	28	609	146	Left	Alive
	14	F	10.3	BA	3635	41.0	Vascular complication	10	873	95	Left	Alive

BA biliary atresia, ALF acute liver failure, PFIC-1 progressive familial intrahepatic cholestasis type-1, FH fulminant hepatitis, Wilson Wilson’s disease, PSC primary, sclerosing cholangitis